KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardlytics (CDLX) Research & Development (2017 - 2025)

Cardlytics (CDLX) has disclosed Research & Development for 9 consecutive years, with $8.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 19.5% year-over-year to $8.0 million, compared with a TTM value of $39.8 million through Dec 2025, down 19.84%, and an annual FY2025 reading of $39.8 million, down 19.84% over the prior year.
  • Research & Development was $8.0 million for Q4 2025 at Cardlytics, down from $8.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $14.8 million in Q2 2023 and bottomed at $6.2 million in Q1 2021.
  • Average Research & Development over 5 years is $11.7 million, with a median of $12.1 million recorded in 2021.
  • The sharpest move saw Research & Development soared 140.78% in 2021, then crashed 33.31% in 2025.
  • Year by year, Research & Development stood at $11.8 million in 2021, then increased by 25.32% to $14.8 million in 2022, then decreased by 15.47% to $12.5 million in 2023, then decreased by 20.91% to $9.9 million in 2024, then fell by 19.5% to $8.0 million in 2025.
  • Business Quant data shows Research & Development for CDLX at $8.0 million in Q4 2025, $8.8 million in Q3 2025, and $11.3 million in Q2 2025.